A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus

Inclusion Criteria: * Signed informed consent obtained before any study-related activities (study-related activities are any procedure related to extraction of data according to the protocol) * Male or female patients at least 18 years of age at time of informed consent * Diagnosis of T2DM (type 2 diabetes mellitus) * Xultophy® initiation prescribed at least 6 months before inclusion in this study (i.e., date of signed informed consent). Patients may or may not be continuing Xultophy® at study inclusion * Minimum available data:a.) At the time of Xultophy® prescription: HbA1c value (or if unavailable, the most recent HbA1c value within 6 months before the first Xultophy® prescription);b.) At 6 months plus/minus 45 days after first Xultophy® prescription: HbA1c value Exclusion Criteria: * Type 1 diabetes * Previous participation in this study. Participation is defined as having provided informed consent * Participation in a clinical trial within 6 months before or 12 months after the first Xultophy® prescription (Participation in a non-interventional study is not an exclusion criteria) * Mental incapacity, unwillingness or inability to provide informed consent, or language barriers precluding adequate understanding or co-operation